FAST STATS
CDC COVID-19 variants, cases and vaccinations tracking
B.1.1.7
is the most common variant of the SARS- CoV-2 virus circulating in the United States and has been reported in all 50 states, the District of Columbia, and Puerto Rico.
5
variants of concern in the United States are being monitored by the CDC; none of the
variants circulating in the United States are classifi ed as variants of high consequence.
27.2%
of COVID-19 cases in the United States were estimated from early March data to have been caused by the B.1.1.7 variant.
of the proportion of cases are estimated to be caused by the B.1.429 variant.
of the proportion of cases are estimated to be caused by the B.1.427 variant.
of the current COVID-19 cases are estimated for both the P.1 and B.1.351 variants.
9.1% 4.3% 0.5% 14TH
of December 2020 is when the US COVID-19 Vaccination Program began; 174.9 million
vaccine doses have been administered as of April 8, 2021.
112.0 MILLION
people, or 33.7% of the US population, are estimated overall to have received at least one dose of vaccine.
66.2 MILLION
people, or 19.9% of the US population, are estimated to have been fully vaccinated.*
*People who are fully vaccinated (formerly “receiving 2 doses”) represents the number of people who have received the second dose in a two-dose COVID-19 vaccine series or one dose of the single-shot J&J/Janssen COVID-19 vaccine.
Note: Data collected on 4/12/21.
Citation: COVID DATA TRACKER WEEKLY REVIEW, Updated Apr. 9, 2021, Interpretive Summary for April 9, 2021, https://www.
cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html
Photo credit: Romolo Tavani |
stock.adobe.com
NEWSWIRE
IAHCSMM Board of Directors announced
The International Association of Health- care Central Service Materiel Management (IAHCSMM) announced the election results for four Board of Director positions. Marjorie Wall, MLOS, CRCST, CIS, CHL, CSBB, Director of Sterile Process- ing for Kaiser Permanente in Downey, California, has been elected as the Associa- tion’s next President-Elect. She will serve consecutive one-year terms as President- Elect (2021-2022), President (2022-2023) and Past President (2023-2024). Wall pre- viously served a two-year term as a Direc- tor on the IAHCSMM Board (2019-2021). Joining Wall are the following three new Directors, all of whom will serve a two-year term (2021-2023): Arlene Bush, CRCST, CIS, CHL, CER, Systems Educator for Sterile Processing and Quality Audit- ing for AdventHealth Central Florida Division in Orlando, Florida; Tracy Dav- enport, BHA, CRCST, CIS, CHL, Manager of Sterile Processing (Operations) for Northside Hospital Atlanta (Georgia); and Alison Sonstelie, CRCST, CIS, CHL, Sterile Processing Lead Coordinator for Sanford Health in Fargo, North Dakota. “It is a privilege to welcome each of
these new members to the IAHCSMM Board of Directors,” said IAHCSMM Executive Director Susan Adams, BS, CAE. “Each brings to the IAHCSMM Board their rich professional experience and strong dedication to the Sterile Pro- cessing discipline, which will lend itself well to supporting the Association and the needs of our growing membership.” The new oard members will take offi ce on May 1, 2021.
FDA warning on infections associated with reprocessed urological endoscopes The U.S. Food and Drug Administra- tion (FDA) alerted healthcare providers, including those working in reprocessing units in healthcare facilities, about the risk of infections associated with reprocessed urological endoscopes, including cysto- scopes, ureteroscopes, and cystourethro- scopes, used for viewing and accessing the urinary tract.
The FDA has received numerous Medi- cal Device Reports (MDRs) which describe patient infections post procedure or other possible contamination issues associated with reprocessing these devices. The FDA is currently investigating the potential causes and contributing factors associated with the reported infections and contami- nation issues. While some reports indicate possible inadequate reprocessing or main-
6 May 2021 • HEALTHCARE PURCHASING NEWS •
hpnonline.com
tenance issues (for example, device failed leak testing) as a potential cause, the FDA is also evaluating other potential issues, including reprocessing instructions in the labeling and device design. The FDA is emphasizing the importance of following the manufacturer’s labeling and reprocessing instructions for these devices, including accessory components, for cleaning and subsequent processing to minimize the risk of infection. Cystoscopes, cystourethroscopes, and ureteroscopes are used by healthcare providers to provide visualization and operative access during diagnostic and therapeutic endoscopic procedures of the urinary tract (e.g., urethra, bladder, ureters, and kidneys), depending on the intended use and design of the device. Since 2017, the FDA has received over 450 MDRs which describe patient infec- tions post procedure or other possible contamination issues associated with reprocessing these devices. In those reports which provided the name of the device manufacturer, either Olympus Corporation or Karl Storz were cited. However, the FDA has not concluded that such risks are limited to a particu- lar manufacturer’s devices nor that any specifi c manufacturer or brand of these devices is associated with higher risks than others. Of these reports, there were three death reports which occurred outside of the United States, submitted by Olympus Corporation. The three reports describe patients who developed Pseudomonas aeruginosa infections post procedure.
Two of the death reports were associ- ated with the use of a forceps/irrigation plug (MAJ-891), which is an accessory component used to control water fl ow and enable access to the working channel of the endoscope. It was reported by Olym- pus that the isolates from clinical samples matched strains of Pseudomonas aerugi- nosa isolated from the forceps/irrigation plug (MAJ-891). The third patient death involved a cystoscope, and the report noted that the cystoscope did not pass a leak test. Failure to pass a leak test indi- cates the cystoscope was damaged and could be a potential source of infection. It is unknown whether or to what degree the reported infections contributed to the patient deaths, and patient co-morbidities may have been a factor.
The potential causes and contributing factors associated with the reported infec- tions or contamination issues are under review, including reprocessing methods, reprocessing instructions in the labeling, and device design. HPN
Page 8
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
